Special Purpose Exit Company (SPEC)
Devinebio creates entities (SPECs) to develop drug assets for a specific indications. Five areas are monitored per each SPEC: population, biomarkers, leads, IP, and regulatory. A SPEC’s assets are moved through the milestones of preIND, IND, preNDA and NDA. As a drug asset progresses, it becomes de-risked and it increases in value. Once a drug asset has achieved IND-enabled status, it will have matured enough to be ready for partnering with Pharma.
FUS Therapeutics
Variations in FUS lead can cause amyotrophic lateral sclerosis, frontotemporal dementia, and hereditary essential tremor.
STXBP1 Therapeutics
Variations throughout STXBP1 lead to epilepsy, intellectual disability, and developmental delay.
CADASIL Therapeutics
Variations in the ectodomain of NOTCH3 lead to microbleeds in the brain that can cause hemorrhagic stroke.
AARS1 Therapeutics
Variations in AARS1 gene can cause Charcot-Marie-Tooth disease, and Developmental and Epileptic Encephalopathy.
CTNNB1 Therapeutics
pathogenic variants in CTNNB1 can cause Severe Intellectual Disability-Progressive Spastic Diplegia Syndrome, and various cancers